Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.59 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.59 |
| ▸ | BRD2 | P25440 | 2/20 | 0.59 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22730541 | 0.95 | BRD4 (0.63) | BRD4MAPK14BRDTBRD2BRD3 | |
| SCHEMBL22730463 | 0.92 | BRD4 (0.71) | BRD4MAPK14BRDTBRD2BRD3 | |
| SCHEMBL22730361 | 0.92 | MAPK14 (0.71) | BRD4MAPK14BRDTBRD2BRD3 | |
| SCHEMBL22730365 | 0.92 | BRD4 (0.71) | BRD4MAPK14BRDTBRD2BRD3 | |
| SCHEMBL22730439 | 0.92 | BRD4 (0.73) | BRD4MAPK14BRDTBRD2BRD3 | |
| SCHEMBL22730455 | 0.91 | BRD4 (0.73) | BRD4MAPK14BRDTBRD2BRD3 | |
| SCHEMBL1640742 | 0.88 | MAPK14 (0.57) | BRD4MAPK14GPR119 | |
| SCHEMBL22730370 | 0.86 | MAPK14 (0.61) | BRD4MAPK14BRDTBRD2BRD3 | |
| SCHEMBL22730559 | 0.84 | BRD4 (0.72) | BRD4MAPK14BRDTBRD2BRD3 | |
| SCHEMBL22730462 | 0.83 | BRD4 (0.83) | BRD4MAPK14BRDTBRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | BRDT, BRD4, BRD3 | BRD4 2/4885MAPK14 2751/4885BRDT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.